Previous 10 |
By Andy Acker, CFA & Daniel Lyons, Ph.D., CFA & John Scotti, D.Phil. The biotech industry is experiencing a renaissance, with the U.S. approving a record number of novel therapies in 2018. But not all drugs are created equal, say members of the Janus Henderson Global Life Sciences...
2018 seems to be ending on a bad note in the markets. December is setting the wrong kind of records, and Q4 has been a bumpy one in general. This is what happens in the stock market sometimes, but it's been easy to forget over the decade-long bull market. We're using the end of the year as a...
By Ethan Lovell Portfolio Manager Ethan Lovell discusses a new proposal to overhaul drug pricing in Medicare Part B and what it could mean for drug manufacturers. Key Takeaways A proposal to lower drug costs would align Medicare Part B drug prices with prices outside the U.S., wher...
We've turned the page to November, and investors across the globe may feel a bit of unconscious relief. Stock markets do fluctuate, but months like October are never fun. And that has been especially acute in biotech. Leading ETFs like IBB and XBI dropped ~15% and 18% respectively in October...
Speaking at the Department of Health & Human Services, the president says both consumers and the government can save money if drugs were priced along the lines of that of other countries (i.e., Canada). More news on: iShares Nasdaq Biotechnology ETF, Health Care Select Sect SPDR ETF,...
By Evan McCulloch, Senior Vice President, Director of Research Franklin Equity Group ® Portfolio Manager, Franklin Biotechnology Discovery Fund Franklin Equity Group's Evan McCulloch explains why higher rates of drug utilization and healthcare spending are lending support to the b...
News, Short Squeeze, Breakout and More Instantly...
ProShares UltraPro Short NASDAQ Biotechnology Company Name:
ZBIO Stock Symbol:
NASDAQ Market:
ProShares UltraPro Short NASDAQ Biotechnology Website: